It is made available under a CC-BY-NC-ND 4.0 International license .

1	MicroRNA-146a polymorphisms are Associated with Psoriasis Vulgaris
2	Running Title: MicroRNA-146a and Psoriasis
3	Key words: Psoriasis Vulgaris; MicroRNA-146a; SNPs; Chinese
4	Counts: Manuscript Words count <u>1680;</u> Tables count <u>3;</u> Figures <u>0.</u>
5	Names of authors:
6	Kunju Zhu <sup>1,2</sup> <sup>#</sup> , Shijie Li <sup>2</sup> , Lifan Liang <sup>1</sup>
7	Names of the institutions:
8	1. The Department of Biomedical Informatics; School of medicine; University of Pittsburgh, USA
9	2. Department of Dermatology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
10	<sup>#</sup> Correspondence author:
11	Kunju Zhu
12	Email: <u>kunju.pitt@gmail.com</u>
13	Address: 5607 Baum Blvd, Pittsburgh, PA 15206-3701
14	<b>Telephone:</b> 1-412-403-9009
15	Any conflict of interest disclosures:
16	The data is an original data, has not been published before and is not being considered for publication
17	elsewhere. The authors state no conflict of interest.
18	Abbreviations:
19	SNPs: single nucleotide polymorphisms;
20	<b>PsV:</b> psoriasis vulgaris;
21	<b>PBMCs:</b> peripheral blood mononuclear cells;
22	<b>NF-κB:</b> nuclear factor-kappaB;
23	<b>IRAK1:</b> IL-1 receptor associated kinase 1;
24	<b>TNF-</b> $\alpha$ : tumor necrosis factor- $\alpha$ ;
25	IL: interleukin;
26	CI: confidence internal;
27	PASI: Psoriasis Area and Severity Index.
28	

It is made available under a CC-BY-NC-ND 4.0 International license .

# <sup>29</sup> Abstract:

30 MicroRNA-146a acts as a critical physiological brake role to prevent the overactivation 31 of inflammatory response pathways and was a key negative regulator of autoimmunity. Ets-1 could bind to the MicroRNA-146a promoter region as a regulator of 32 33 MicroRNA-146a expression in vitro. IRAK1 is a prominent target of MicroRNA-146a that help it to negatively regulate the release of IL8. This study aimed to investigate the 34 35 association of MicroRNA-146a, Ets-1(negative regulator) and IRAK1(target) polymorphisms with Psoriasis Vulgaris(*PsV*), the most prevalent chronic inflammatory 36 skin disease in adults, in a Southern Chinese cohort. Seven SNPs in microRNA-146a 37 (rs2431697; rs2910164; rs57095329), Ets-1(rs10893872; rs1128334) 38 and 39 IRAK1(rs1059703; rs3027898) genes were genotyped in 673 subjects (360 PsV cases and 313 controls) by SNaPshot Multiplex Kit (Applied Biosystems Co., USA). We found 40 41 significant difference in the genotype and allele frequencies of rs2431697 and rs2910164 42 in MicroRNA-146a gene between the PsV cases and the controls. The dominant model genotype (CC+CT) (p=0.019; OR=1.463) and allele (C) (p=0.027; OR=1.496) of 43 44 rs2431697 and the GG genotype (p=0.027; OR=1.582) and allele (G) of rs2910164 were 45 associated with an increased risk of PsV. There was no association of the SNPs with the clinical traits of PsV. Our data provide preliminary evidence that the rs2431697 and 46 rs2910164 polymorphism in the microRNA-146a gene may be involved in the genetic 47 susceptibility to PsV in Southern Chinese. Although further function studies will be 48 required to identify the details of the process, the findings could make a significant step 49 forward in our understanding of the genetic contribution to psoriasis. 50

51

It is made available under a CC-BY-NC-ND 4.0 International license .

53	What's already known about this topic?							
54	• M	icroRNA-146a is one of the most highly associated MicroRNA to psoriasis.						
55	• M	icroRNA-146a acts as a critical physiological brake role to prevent the overactivation						
56	of	inflammatory response pathways and was a key negative regulator of autoimmunity.						
57								
58								
59	What	does this study add?						
60	• Oı	ur data provide preliminary evidence that the rs2431697 and rs2910164 polymorphism						
61	in	the microRNA-146a gene are involved in the genetic susceptibility to PsV in						
62	So	outhern Chinese.						

It is made available under a CC-BY-NC-ND 4.0 International license .

### 64 Introduction:

Psoriasis is one of the most common skin disorders resulting from a complex interplay among the susceptibility genes and autoimmune system<sup>1</sup>. Psoriasis vulgaris (PsV), the most common subtype of psoriasis, is characterized by the emergence of hyperkeratosis, parakeratosis and orthokeratosis<sup>2</sup>. However, the molecules pathogenesis of psoriasis is still not completely elucidated.

70 The microRNAs represent a class of is short and regulatory RNAs that regulate RNA 71 silencing and post-transcriptional process. Recently studies have also shown that the noncoding RNAs (including microRNAs) may be a crucial regulator in human life and so 72 many human diseases<sup>3</sup>. Furthermore, the majority of protein-coding genes may be regulated 73 74 by microRNAs. Accordingly, microRNAs have been implicated in almost all biological processes, in particular cell differentiation, development and the signaling pathways<sup>3</sup>. In 75 76 recent years, evidence is accumulating for the role of microRNAs in the pathogenesis of psoriasis rapidly<sup>4</sup>. Specifically, many studies have confirmed that single nucleotide 77 polymorphisms (SNPs) located in microRNAs genes associated with the susceptibility to 78 psoriasis<sup>4,5</sup>. 79

80 Of the susceptibility microRNAs to psoriasis, MicroRNA-146a is one of the most highly associated MicroRNA to psoriasis <sup>6-8</sup>. Several studies have found that MicroRNA-146a 81 Increased both in the epidermal and dermal compartments of psoriatic skin<sup>7,9</sup>. 82 Chatzikyriakidou et al<sup>10</sup> have shown the association between psoriatic arthritis risk in a 83 84 cohort of patients with psoriasis from Greece and specific polymorphisms found in MicroRNA-146a (rs2910164) and one of its targets IRAK1 (rs3027898, rs1059703). In his 85 study, a very strong association with the rs3027898 IRAK1 variant was also observed <sup>10</sup>. 86 Specifically, the rs2910164G allele resulted in reduced levels of MicroRNA-146a and 87 impairment of its ability to regulate endothelial growth factor receptor, an important 88 proliferative signal in keratinocytes and psoriasis skin<sup>11</sup>. 89

90 On the other hand, previously study have identified that ETS proto-oncogene 1,

It is made available under a CC-BY-NC-ND 4.0 International license .

transcription factor (ETS1) could affects MicroRNA-146a promoter activity markedly in 91 vitro, by binding the MicroRNA-146a promoter region<sup>12</sup>. Furthermore, knockdown of ETS1 92 impaired the induction of miR-146a, whereas overexpression of ETS1 enhanced the 93 94 induction of MicroRNA-146a in vivo experiments. Actually, ETS1 is involved in various immune responses. ETS1 plays a role in immunity, angiogenesis, and cancer progression, 95 and is expressed in B cells, T cells, natural killer cells, endothelial cells, and cancer cells<sup>13-15</sup>. 96 In T cells, reduction of T helper (Th) 1 cytokine, interferon  $\gamma$ , and decrease in regulatory T 97 cells (Tregs) were observed in Ets1-deficient mice. On the other hand, Th17 differentiation 98 was enhanced by Ets1 deficiency<sup>13-15</sup>. It has also been shown that SNP rs1128334 and 99 rs10893872 located in the 3'-untranslated region (3'-UTR) of Ets-1 are on putative miRNA 100 binding sites and are both associated with SLE in Asian populations<sup>12</sup>. All these results may 101 suggest that Ets-1 influences the activity of MicroRNA-146a and it may take some role in the 102 103 immunity pathogenesis of psoriasis.

In this study, we aimed to examined the association of MicroRNA-146a, Ets-1(its negative regulator) and IRAK1(its target) gene polymorphisms with PsV in a Southern Han Chinese cohort.

107

It is made available under a CC-BY-NC-ND 4.0 International license .

### 109 Materials and methods

#### 110 Clinical evaluation and Anthropometric measurements of patients and controls

The detailed method of clinical characteristics evaluation and anthropometric measurements 111 had been described previously<sup>16</sup>. In shortly, General information of all subjects include age, 112 gender, family history, Psoriasis Area and Severity Index (PASI)<sup>17,18</sup> were recorded. The 113 positive family history was considered if at least one of the first- and second-degree relatives 114 was suffered from psoriasis. PASI score below 6 was defined as mild, and above 6 as severe 115 disease based on median distribution. A total of 360 cases and 313 controls at age of 15 years 116 or more were recruited from 2009 to 2016 in Southern China. The study protocol was 117 approved by the ethical committee of Affiliated Hospital of Guangdong Medical University 118 in compliance with the Helsinki Declaration, and written informed consents were obtained 119 120 from all participants.

## 121 **DNA isolation and genotyping**

Genomic DNAs were extracted in accordance with standard protocols from peripheral blood cells by established method<sup>19</sup>. Genotyping of 7 SNPs in microRNA-146a (rs2431697; rs2910164; rs57095329), IRAK1 (rs1059703; rs3027898), Ets-1(rs10893872; rs1128334) genes were determined using SNaPshot Multiplex Kit (Applied Biosystems Co., USA).

#### 126 Statistical analyses

P<0.05 was the criterion of statistical significance, and all statistical tests were two-sided. Characteristics differences between cases and controls were assessed with the *t* test, the Pearson's Chi-square test by the SPSS 13.0. The SNP was analyzed for an association with the disease by means of comparison frequency of the minor allele and genotypes, and Hardy–Weinberg equilibrium among controls was confirmed with Chi-squared test for all SNPs. We also performed case-only subtype analyses to examine associations between two significant SNPs genotypes with the clinical traits of PsV.

134

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 136 **Results**

#### 137 Subjects characteristics

138 A total of 360 cases (275 men: 185 women; 37.63±15.33 years) and 313 controls (185 men:

139 128 women;  $35.77\pm14.87$  years) were investigated and matched on age and sex (p>0.05). For

140 patients, PASI ( $8.83\pm7.57$ ), age of onset ( $30.44\pm16.06$  and 258 Early-onset ( $\leq 40$  years): 102

Later-onset (> 40 years)) and family history (ratio of familial: sporadic cases=75:285) was

- 142 recorded (Table 1).
- 143

#### 144 Association between seven polymorphisms and the risk of PsV

145 The genotype frequency distributions for 7 SNPs investigated were consistent with 146 Hardy-Weinberg equilibrium in the control group (p>0.05). The comparison of allele 147 distributions revealed that two SNPs (rs2431697, rs2910164) of them were significant associated with the risk of PsV (p < 0.05). For rs2431697, the minor allele C was present in 148 149 15.56% of patients and 11.18% of controls; and significant differences was also observed in 150 dominance model (p < 0.01), but the recessive model is not. Then for rs2910164, the minor 151 allele G was present in 43.75% of patients and 36.90% of controls; and significant 152 differences was also observed in recessive model (p < 0.01), but the dominance model is not 153 (**Table 2**).

154

#### Association between two risk SNPs (rs2431697, rs2910164) associated with the clinical

We further performed a stratified analysis according to the age of onset, family history and PASI subphenotypes to detect the distribution of the rs2431697 and rs2910164 genotypes in clinical phenotype of PsV. However, there were no significant differences found in subphenotypes of family history or PASI between patients positive and those negative for a particular phenotype (**Table 3**).

161

It is made available under a CC-BY-NC-ND 4.0 International license .

## 163 **Discussion:**

We conducted the study to evaluate the association between 7 SNPs of MicroRNA-146a gene, Ets-1(its negative regulator) and IRAK1(its target) polymorphisms and risk factors on PsV.

167 As we know, MicroRNAs are an abundant class of small noncoding RNA molecules, and have been recently recognized as an important regulator in immune homeostasis <sup>3</sup>. As 168 MicroRNA-146a is a crucial negative regulator of the immune response by negatively 169 regulating NF- $\kappa B$  dependent inflammatory signals via direct targeting of IL-1 170 receptoreassociated kinase 1 (IRAK1)  $^{20,21}$ . NF- $\kappa B$  is a protein transcription factor and a key 171 172 regulatory element in a variety of immune and inflammatory pathways, in cellular 173 proliferation and differentiation. Furthermore,  $NF \cdot \kappa B$  has been hypothesized to connect the altered keratinocyte and immune cell behavior that characterizes the psoriatic milieu<sup>21,22</sup>. 174

Moreover, recent studies have demonstrated that SNPs located either in the pre-miRNAs 175 or within miRNA binding sites may contribute to the susceptibility to diseases. Within 176 MicroRNA-146a, several SNPs (rs2910164 and rs2431697) which could lead to the 177 alteration of microRNA function or expression have been noted<sup>23,24</sup>. Specifically, rs2910164 178 179 in the pre-miRNA sequence is thought to result in reduced levels of both the pre and mature miRNA. And previously studied found the association between psoriatic arthritis risk in a 180 cohort of patients with psoriasis from Greece and specific polymorphisms found in 181 microRNA-146a (rs2910164) and one of its known targets, IRAK1 (rs3027898, rs1059703) 182 <sup>10</sup>. In contrast, a separate study showed that the rs2910164 microRNA-146a allele was 183 associated with increased psoriasis susceptibility in Han Chinese patients<sup>11</sup>. The rs2910164 184 variant C-allele also play a role in the progression of PsA in the South African Indian 185 population<sup>25</sup>. Specifically, the rs2910164G allele resulted in reduced levels of 186 microRNA-146a and impairment of its ability to regulate endothelial growth factor receptor, 187 an important proliferative signal in keratinocytes and psoriasis skin<sup>11</sup>. Srivastava *et al* report 188 protective association of a functional polymorphism in the MicroRNA-146a precursor 189 (rs2910164). Genetic deficiency in MicroRNA-146a leads to earlier onset and exacerbated 190 pathology of skin inflammation, with increased expression of IL-17-induced 191

It is made available under a CC-BY-NC-ND 4.0 International license .

192 keratinocyte-derived inflammatory mediators, epidermal hyperproliferation, and increased 193 neutrophil. infiltration. Moreover, they also shown that MicroRNA-146a -deficient mice do not resolve inflammation after discontinuation of imiquimod challenge. The overexpression 194 of MicroRNA-146a suppressed, whereas its inhibition enhanced, IL-17-driven inflammation 195 in keratinocytes. Functionally, MicroRNA-146a impairs the neutrophil chemoattractant 196 capacity of keratinocytes. Finally, delivery of MicroRNA-146a mimics into the skin leads to 197 amelioration of psoriasiform skin inflammation, decreased epidermal proliferation, and 198 neutrophil infiltration. Their results define a crucial role for MicroRNA-146a in modulating 199 IL-17–driven inflammation in the skin<sup>23</sup>. 200

201 In addition, strong evidence indicates that rs2910164 leads to increased or decreased 202 microRNA-146a expression in a cell type-dependent manner. For instance, Jazdzewski et al. 203 reported that rs2910164 C allele displayed a 1.8-fold lower level of mature MicroRNA-146a compared to those harboring the G allele<sup>26</sup>. Likewise, Xu et al. found that the G-allelic 204 MicroRNA-146a precursor yielded more mature MicroRNA-146a compared to the C 205 allelic precursor in the 293T cell line<sup>27</sup>. On the other hand, Shen et al. found that 206 MicroRNA-146a expression was 60% higher in the C allele than the G allele in the MCF-7 207 cell, a model system for breast cancer<sup>28</sup>. The disparate effects of the rs2910164 C allele on 208 the expression level of MicroRNA-146a may explain the equally disparate effects the SNP 209 210 has on autoimmune diseases that are localized to different tissues or affect different cell types such as psoriasis and ankylosing spondylitis<sup>24</sup>. 211

In our study, we found the allele and genotypes of rs2910164 and rs2431697 of MicroRNA-146a associated with the risk of PsV. The associations of the other SNPs within the susceptibility loci remain unclear and further studies are necessary to achieve better understanding the genetic components of PsV. Despite the fact that the function experiments were not carrying out to further illustrate this phenomenon from the level of genetic epidemiology. The findings could make a significant step forward in our understanding of the genetic contribution to psoriasis.

It is made available under a CC-BY-NC-ND 4.0 International license .

## 220 Acknowledgment:

- 221 We are most grateful to the members of all the patients, the controls and their families who
- have so willingly participated in this study. This work was supported by grants from the
- 223 China Natural Science Foundation (No. 81301351). The funders had no role in study
- design, data collection and analysis, decision to publish, or preparation of the manuscript.
- 225
- 226
- 227
- 228

It is made available under a CC-BY-NC-ND 4.0 International license .

229	Refe	rences:
230	1	Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352: 1899-912.
231	2	Krueger GG, Duvic M. Epidemiology of psoriasis: clinical issues. J Invest Dermatol 1994; 102:
232		14S-8S.
233	3	Esteller M. Non-coding RNAs in human disease. Nature reviews. Genetics 2011; 12: 861-74.
234	4	Hawkes JE, Nguyen GH, Fujita M et al. microRNAs in Psoriasis. J Invest Dermatol 2016; 136:
235		365-71.
236	5	Sonkoly E, Stahle M, Pivarcsi A. MicroRNAs: novel regulators in skin inflammation. Clin Exp
237		Dermatol 2008; <b>33</b> : 312-5.
238	6	Sonkoly E, Wei T, Janson PC et al. MicroRNAs: novel regulators involved in the pathogenesis of
239		psoriasis? PLoS One 2007; 2: e610.
240	7	Xia J, Joyce CE, Bowcock AM et al. Noncanonical microRNAs and endogenous siRNAs in normal
241		and psoriatic human skin. Hum Mol Genet 2013; 22: 737-48.
242	8	Zibert JR, Lovendorf MB, Litman T et al. MicroRNAs and potential target interactions in psoriasis. J
243		Dermatol Sci 2010; <b>58</b> : 177-85.
244	9	Lovendorf MB, Mitsui H, Zibert JR et al. Laser capture microdissection followed by next-generation
245		sequencing identifies disease-related microRNAs in psoriatic skin that reflect systemic microRNA
246		changes in psoriasis. Exp Dermatol 2015; 24: 187-93.
247	10	Chatzikyriakidou A, Voulgari PV, Georgiou I et al. The role of microRNA-146a (miR-146a) and its
248		target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility. Scandinavian journal of
249		<i>immunology</i> 2010; <b>71</b> : 382-5.
250	11	Zhang W, Yi X, Guo S et al. A single-nucleotide polymorphism of miR-146a and psoriasis: an
251		association and functional study. J Cell Mol Med 2014; 18: 2225-34.
252	12	Luo X, Yang W, Ye DQ et al. A functional variant in microRNA-146a promoter modulates its
253		expression and confers disease risk for systemic lupus erythematosus. PLoS Genet 2011; 7: e1002128.
254	13	Garrett-Sinha LA. Review of Ets1 structure, function, and roles in immunity. Cell Mol Life Sci 2013;
255		<b>70</b> : 3375-90.
256	14	Kawasaki A, Yamashita K, Hirano F et al. Association of ETS1 polymorphism with granulomatosis
257		with polyangiitis and proteinase 3-anti-neutrophil cytoplasmic antibody positive vasculitis in a
258		Japanese population. J Hum Genet 2018; 63: 55-62.
259	15	Russell L, Garrett-Sinha LA. Transcription factor Ets-1 in cytokine and chemokine gene regulation.
260		<i>Cytokine</i> 2010; <b>51</b> : 217-26.
261	16	Zhu K-J, Liu Z, Liu H et al. An association study on the CHRNA5/A3/B4 gene cluster, smoking and
262		psoriasis vulgaris. Archives of dermatological research 2014; <b>306</b> : 939-44.
263	17	Fredriksson T, Pettersson U. Severe psoriasisoral therapy with a new retinoid. Dermatologica 1978;
264		<b>157</b> : 238-44.
265	18	Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global
266		Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51:
267		563-9.
268	19	Grimberg J, Nawoschik S, Belluscio L et al. A simple and efficient non-organic procedure for the
269		isolation of genomic DNA from blood. Nucleic Acids Res 1989; 17: 8390.
270	20	Meisgen F, Xu Landen N, Wang A et al. MiR-146a negatively regulates TLR2-induced inflammatory
271	_	responses in keratinocytes. J Invest Dermatol 2014; <b>134</b> : 1931-40.
272	21	O'Connell RM, Rao DS, Baltimore D. microRNA regulation of inflammatory responses. Annu Rev

It is made available under a CC-BY-NC-ND 4.0 International license .

273		Immunol 2012; <b>30</b> : 295-312.
274	22	Taganov KD, Boldin MP, Chang KJ et al. NF-kappaB-dependent induction of microRNA miR-146, an
275		inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006;
276		<b>103</b> : 12481-6.
277	23	Srivastava A, Nikamo P, Lohcharoenkal W et al. MicroRNA-146a suppresses IL-17-mediated skin
278		inflammation and is genetically associated with psoriasis. J Allergy Clin Immunol 2017; 139: 550-61.
279	24	Park R, Lee WJ, Ji JD. Association between the three functional miR-146a single-nucleotide
280		polymorphisms, rs2910164, rs57095329, and rs2431697, and autoimmune disease susceptibility: A
281		meta-analysis. Autoimmunity 2016; 49: 451-8.
282	25	Maharaj AB, Naidoo P, Ghazi T et al. MiR-146a G/C rs2910164 variation in South African Indian and
283		Caucasian patients with psoriatic arthritis. BMC medical genetics 2018; 19: 48.
284	26	Jazdzewski K, Murray EL, Franssila K et al. Common SNP in pre-miR-146a decreases mature miR
285		expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2008; 105:
286		7269-74.
287	27	Xu T, Zhu Y, Wei QK et al. A functional polymorphism in the miR-146a gene is associated with the
288		risk for hepatocellular carcinoma. Carcinogenesis 2008; 29: 2126-31.
289	28	Shen J, Ambrosone CB, DiCioccio RA et al. A functional polymorphism in the miR-146a gene and
290		age of familial breast/ovarian cancer diagnosis. Carcinogenesis 2008; 29: 1963-6.
291		
• • •		
292		

It is made available under a CC-BY-NC-ND 4.0 International license .

# **TABLES LEGENDS**

- **Table 1.** The characteristics of PsV cases and controls
- **Table 2.** OR estimates of effects on the risk of PsV
- **Table 3.** OR estimates of risk SNPs genotypes on the clinical traits of PsV.

It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1. The characteristics of PsV cases and controls							
Variables	Cases (n = 360)	Controls (n = 313)	<i>p</i> -Value				
Age(mean±sd, years)	37.63±15.33	35.77±14.87	0.54				
Females, n	185	128	0.95				
Males, n	275	185	0.85				
PASI score (mean±sd)	8.63±7.57	-	-				
Mean age of onset (mean±sd, years)	30.44±16.06	-	-				
Early-onset ( $\leq 40$ years), n	256	-	-				
Later-onset (> 40 years), n	99	-	-				
Familial cases, n	74	-	-				
Sporadic cases, n	281	-	-				

Table 1. The characteristics of PsV cases and controls

PASI ;Psoriasis Area and Severity Index

 $\chi 2$  -test for categorical variables.

t-test for quantitative variables;

It is made available under a CC-BY-NC-ND 4.0 International license .

300

## Table 2. OR estimates of effects on the risk of PsV

Gene	SNPs	Comparisons	Minor allele and Genotype Frequency				OR(95% CI)	p-Value
			Case	es(n=360)	Control	ls(n=313)	-	
MicroRNA-146a	rs2431697	C(vs.T)	112	15.56%	70	11.18%	1.463(1.062-2.015)	0.019*
		CC(vs.CT+TT)	12	3.33%	6	1.92%	1.764(0.654-4.757)	0.256
		CC+CT(vs.TT)	100	27.78%	64	20.45%	1.496(1.045-2.142)	0.027*
MicroRNA-146a	rs2910164	G(vs.C)	315	43.75%	231	36.90%	1.330(1.068-1.656)	0.011*
		GG(vs.GC+CC)	74	20.56%	44	14.06%	1.582(1.051-2.380)	0.027*
		GG+GC(vs.CC)	241	66.94%	187	59.74%	1.365(0.996-1.870)	0.053
MicroRNA-146a	rs57095329	G(vs.A)	139	19.31%	139	22.20%	0.838(0.644-1.092)	0.190
		GG(vs.GA+AA)	12	3.33%	17	5.43%	0.600(0.282-1.277)	0.181
		GG+GA(vs.AA)	127	35.28%	122	38.98%	0.853(0.624-1.168)	0.321
IRAK1	rs1059703	A(vs.G)	149	20.69%	146	23.32%	0.858(0.662-1.111)	0.245
		AA(vs.AG+GG)	51	14.17%	52	16.61%	0.828(0.544-1.261)	0.379
		AA+AG(vs.GG)	98	27.22%	94	30.03%	0.871(0.623-1.218)	0.421
IRAK1	rs3027898	A(vs.C)	145	20.14%	140	22.36%	0.875(0.674-1.137)	0.319
		AA(vs.AC+CC)	51	14.17%	50	15.97%	0.868(0.569-1.326)	0.512
		AA+AC(vs.CC)	94	26.11%	90	28.75%	0.876(0.624-1.229)	0.443
ETS-1	rs10893872	C(vs.T)	292	40.56%	272	43.45%	0.888(0.715-1.103)	0.283
		CC(vs.CT+TT)	58	16.11%	61	19.49%	0.793(0.534-1.179)	0.252
		CC+CT(vs.TT)	234	65.00%	211	67.41%	0.898(0.652-1.237)	0.510
ETS-1	rs1128334	T(vs.C)	252	35.00%	239	38.18%	0.872(0.698-1.089)	0.227
		TT(vs.TC+CC)	49	13.61%	50	15.97%	0.829(0.541-1.270)	0.388
		TT+TC(vs.CC)	203	56.39%	189	60.38%	0.848(0.624-1.154)	0.295

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 302 Table 3: OR estimates of risk SNPs genotypes on the clinical traits of PsV

303

SNPs	Genotypes Frequency of Cases	Early-onset (≤ 40 years) VS. Later-onset (> 40 years)			nilial cases VS. poradic cases	Mild (PASI ≤6) VS. Severe(PASI >6)	
		p value	OR(95% CI)	p value	OR(95% CI)	p value	OR(95% CI)
rs2431697							
CC	12(3.33%)		1 (referent)		1 (referent)		1 (referent)
СТ	88(24.44%)	0.261	0.495(0.143-1.716)	0.251	2.25(0.603-8.396)	0.693	1.278(0.377-4.336)
TT	260(72.22%)	0.325	0.557(0.171-1.811)	0.298	1.864(0.541-6.418)	0.520	1.466(0.454-4.739)
rs2910164							
GG	74(20.56%)		1 (referent)		1 (referent)		1 (referent)
CG	167(46.39%)	0.056	1.880(0.978-3.611)	0.338	0.704(0.343-1.447)	0.562	0.850(0.492-1.471)
CC	119(33.06%)	0.244	1.509(0.754-3.023)	0.276	0.659(0.311-1.400)	0.830	1.066(0.596-1.905)

304

305

306 OR: odds ratio;

307 CI: confidence internal;

308 PASI: Psoriasis Area and Severity Index.

309 Based on median distribution, PASI < 6.0 was defined as mild psoriasis and 6.0 as severe psoriasis.

310

311